Ventana Sublicensing IP from Gen-Probe for ERG Protein Measurement | GenomeWeb

NEW YORK (GenomeWeb News) – Ventana Medical Systems today announced it is co-exclusively sublicensing certain patents and patents applications from Gen-Probe for the worldwide in vitro diagnostic rights to measure ERG protein expression by immunohistochemistry in prostate tissue.

Ventana, a Roche company, said that the license complements its existing worldwide co-exclusive sublicense under certain patents and patent applications for in situ hybridization for measuring ETS gene rearrangements, such as ERG gene rearrangements in tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.